Bioinformatic strategies for unambiguous identification of prostate specific antigen in clinical samples.

Bioinformatic strategies for unambiguous identification of prostate specific antigen in clinical samples.

Prostate specific antigen (PSA), as a widely used clinical biomarker in prostate cancer diagnostics, exists in multiple molecular forms. However, all of these forms might not be recognized in a given sample by the standard immunoassays. Therefore, we have investigated PSA isoforms, separated by size...

Full description

Bibliographic Details
Main Authors:	Végvári, A, Rezeli, M, Häkkinen, J, Sihlbom, C, Carlsohn, E, Malm, J, Lilja, H, Laurell, T, Marko-Varga, G
Format:	Journal article
Language:	English
Published:	2011

Similar Items

Molecular microheterogeneity of prostate specific antigen in seminal fluid by mass spectrometry.
by: Végvári, Á, et al.
Published: (2012)

Identification of prostate-specific antigen (PSA) isoforms in complex biological samples utilizing complementary platforms.
by: Végvári, A, et al.
Published: (2010)

Acoustic whole blood plasmapheresis chip for prostate specific antigen microarray diagnostics.
by: Lenshof, A, et al.
Published: (2009)

Acoustic whole blood plasmapheresis chip for prostate specific antigen microarray diagnostics.
by: Lenshof, A, et al.
Published: (2009)

Biology of prostate-specific antigen
by: Lilja, H
Published: (2003)

Biology of prostate-specific antigen.
by: Lilja, H
Published: (2003)

Integrated selective enrichment target--a microtechnology platform for matrix-assisted laser desorption/ionization-mass spectrometry applied on protein biomarkers in prostate diseases.
by: Ekström, S, et al.
Published: (2004)

Porous silicon antibody microarrays for quantitative analysis: measurement of free and total PSA in clinical plasma samples.
by: Järås, K, et al.
Published: (2012)

Enzymatic action of prostate-specific antigen (PSA or hK3): substrate specificity and regulation by Zn(2+), a tight-binding inhibitor.
by: Malm, J, et al.
Published: (2000)

Macro/nano-structured silicon as solid support for antibody arrays: Surface design, reproducibility, and assay characteristics enabling discovery of kallikrein gene products for prostate disease diagnostics
by: Ressine, A, et al.
Published: (2005)

Association between polymorphisms in the prostate-specific antigen (PSA) promoter and release of PSA.
by: Sävblom, C, et al.
Published: (2009)

[Isoforms of free prostate-specific antigen]
by: Haese, A, et al.
Published: (2004)

Isoforms of free prostate-specific antigen
by: Haese, A, et al.
Published: (2004)

Prostate-specific antigen and prostate cancer: prediction, detection and monitoring.
by: Lilja, H, et al.
Published: (2008)

Early prostate-specific antigen changes and the diagnosis and prognosis of prostate cancer.
by: Botchorishvili, G, et al.
Published: (2009)

High-speed biomarker identification utilizing porous silicon nanovial arrays and MALDI-TOF mass spectrometry.
by: Finnskog, D, et al.
Published: (2006)

Prostate-specific antigen and related isoforms in the diagnosis and management of prostate cancer.
by: Haese, A, et al.
Published: (2004)

Taxon-specific evolution of glandular kallikrein genes and identification of a progenitor of prostate-specific antigen.
by: Olsson, A, et al.
Published: (2004)

Molecular insights into substrate specificity of prostate specific antigen through structural modeling.
by: Singh, P, et al.
Published: (2009)

Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer.
by: Denmeade, SR, et al.
Published: (2003)

An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection.
by: Vickers, A, et al.
Published: (2011)

Reverse-phase versus sandwich antibody microarray, technical comparison from a clinical perspective.
by: Järås, K, et al.
Published: (2007)

Markov chains and unambiguous automata
by: Baier, C, et al.
Published: (2023)

Integrated acoustic immunoaffinity-capture (IAI) platform for detection of PSA from whole blood samples.
by: Ahmad Tajudin, Asilah, et al.
Published: (2013)

Cumulative prostate cancer risk assessment with the aid of the free-to-total prostate specific antigen ratio.
by: Aus, G, et al.
Published: (2004)

Quantification of total apolipoprotein E and its specific isoforms in cerebrospinal fluid and blood in Alzheimer’s disease and other neurodegenerative diseases
by: Melinda Rezeli, et al.
Published: (2015-09-01)

An unambiguous synthesis of Jacareubin /
by: 238391 Jefferson, A, et al.
Published: (1966)

Simultaneous quantification of prostate-specific antigen and human glandular kallikrein 2 mRNA in blood samples from patients with prostate cancer and benign disease.
by: Ylikoski, A, et al.
Published: (2002)

Targeting free prostate-specific antigen for in vivo imaging of prostate cancer using a monoclonal antibody specific for unique epitopes accessible on free prostate-specific antigen alone.
by: Evans-Axelsson, S, et al.
Published: (2012)

Prostate-specific antigen (PSA) protein does not affect growth of prostate cancer cells in vitro or prostate cancer xenografts in vivo.
by: Denmeade, SR, et al.
Published: (2003)

Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer.
by: Vickers, A, et al.
Published: (2009)

Sensitive and specific enzymatic assay for the determination of precursor forms of prostate-specific antigen after an activation step.
by: Niemelä, P, et al.
Published: (2002)

On the use of prostate-specific antigen for screening of prostate cancer in European Randomised Study for Screening of Prostate Cancer.
by: Bangma, C, et al.
Published: (2010)

Markov Chains and Unambiguous Büchi Automata
by: Kiefer, S, et al.
Published: (2016)

Markov chains and unambiguous Büchi automata
by: Baier, C, et al.
Published: (2016)

Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer
by: Becker, C, et al.
Published: (2003)

Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer.
by: Becker, C, et al.
Published: (2003)

Workflow for large-scale analysis of melanoma tissue samples
by: Maria E. Yakovleva, et al.
Published: (2015-09-01)

Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater.
by: Becker, C, et al.
Published: (2000)

Increase in percent free prostate-specific antigen in men with chronic kidney disease.
by: Bruun, L, et al.
Published: (2009)